EXAS earnings call for the period ending March 31, 2024.…
Exact Sciences Shares Drop 10% on Earnings Miss…
Exact Sciences (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth,…
…
A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part…
Exact Sciences EVP sells $140k in company stock…
Citi sees Exact Sciences shares climbing after rivals data disappoints…
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…
…
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…
Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
EXAS earnings call for the period ending December 31, 2023.…
Robust revenues from Exact Sciences (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.…
Exact Sciences (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer…
Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…
…
Exact Sciences projects 17% Q4 revenue growth…
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.…
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy…
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy…
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.…
Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.…
…
EXAS earnings call for the period ending September 30, 2023.…
…
Exact Sciences (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.…
Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…
• Fast jeder Titel in ARKs Flaggschiffstrategie soll im Bereich der künstlichen Intelligenz engagiert sein• Wood setzt auf Unternehmen mit…
Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.…
…
The business is unprofitable, but it has been growing at an impressive rate in recent years....…
Baranick, Brian - Vorstand - Tag der Transaktion: 2023-08-07...…
The company released second-quarter earnings that were improved, but investors were unimpressed....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
The biotechs Q2 numbers were impressive overall, but Wall Street apparently wasnt satisfied....…
EXAS earnings call for the period ending June 30, 2023....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Reports record results, generates positive free cash flow, raises full-year guidance Second-quarter 2023 highlights Total second quarter revenue of $622…
Here is how Abcam PLC Sponsored ADR (ABCM) and Exact Sciences (EXAS) have performed compared to their sector so far…
Latest Ratings for EXAS
DateFirmActionFromTo Feb 2022Wells FargoMaintainsEqual-Weight Feb 2022CitigroupMaintainsNeutral Feb 2022Raymond JamesMaintainsOutperform
View More…
MADISON, Wis., July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic…
Is it a matter of time before Exact Sciences stock starts giving back some of its impressive gains this year?...…
Latest Ratings for EXAS
DateFirmActionFromTo Feb 2022Wells FargoMaintainsEqual-Weight Feb 2022CitigroupMaintainsNeutral Feb 2022Raymond JamesMaintainsOutperform
View More…
Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Lets find out....…
Here is how Exact Sciences (EXAS) and Brookdale Senior Living (BKD) have performed compared to their sector so far this…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Shares of Exact Sciences Corp. EXAS gained more than 7% in premarket trading Wednesday after the company released results from…